Posts tagged RSV
Ladenburg starts Aviragen Therapeutics at buy

Ladenburg Thalmann has launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and $2.50 price target. The stock closed at $1.60 on Tuesday.

“We view Aviragen as an emerging small molecule antiviral story with important proof-of-concept data from two Phase 2 programs - respiratory syncytial virus (RSV) and rhinovirus (HRV) - expected in the next six months,” writes analyst Kevin DeGeeter.

Read More